Fingolimod (FTY720) HCl

Catalog No.S5002

For research use only.

Fingolimod (FTY720) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.

Fingolimod (FTY720) HCl Chemical Structure

CAS No. 162359-56-0

Selleck's Fingolimod (FTY720) HCl has been cited by 91 publications

Purity & Quality Control

Choose Selective S1P Receptor Inhibitors

Other S1P Receptor Products

Biological Activity

Description Fingolimod (FTY720) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.
Targets
S1P receptor [1]
(K562, NK cells )
0.033 nM
In vitro

The inhibitory effect of S1P is revered by various concentrations of FTY720, with IC50 effect of 173 nM. In addition, FTY720 (10 nM) alone exerts no effect on the expression of co-stimulatory molecules. FTY720 reverses the increased expression of HLA-I induced by S1P for both the percentages of cells and the MFI, upon comparing the effect of S1P to the effect of combining S1P with FTY720. [1] Medium and high-dose FTY720-P also enhances the levels of TGF-β1. TGF-β1 and Foxp3 mRNA expression are upregulated in the high-dose FTY720-P group. The proliferation of effector T cells is suppressed significantly in the medium and high-dose FTY720-P group at a Treg/Teff cell ratio of 1:1. At a ratio of 1:1, the proliferation of effector T cells is also suppressed in the high-dose FTY720 group. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human U2OS cells M{TQb2Z2dmO2aX;uJIF{e2G7 MkLpRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDTNXAyKHKnY3XweI9zKGW6cILld5Nm\CCrbjDoeY1idiCXMl;TJINmdGy|IHPvMYV5eHKnc4Ppcoch\UeIUDDhd5Nme3OnZDDhd{Bz\WOncITvdkBqdnSncn7hcIl7[XSrb36gbY51dyCleYTvdIxie21idYPpcochUG:nY3jzeEBlgWVic4ThbY5qdmduIFXDOVA:OC5yMEKg{txONg>? MlzWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzMESxOFQoRjJ{MUC0NVQ1RC:jPh?=
human PC3 cells MWTDfZRwfG:6aXRCpIF{e2G7 MWO3NkBp M4rGe2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bi\nSncjC3NkBpenNiYomgeol1[WxiZInlJIV5[2y3c3nvck9ndG:5IHP5eI9u\XS{aXOgZY5idHm|aYOsJGlEPTB;OT64JO69VS5? MkG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{N{O2N|IoRjJ2MkezOlMzRC:jPh?=
human NALM6 cells MVrDfZRwfG:6aXRCpIF{e2G7 MWe3NkBp MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBRcC2wZXfheIl3\SCqdX3hckBPSUyPNjDj[YxteyCjZoTldkA4OiCqcoOgZpkhfmm2YXyg[JlmKGW6Y3z1d4lwdi:obH;3JIN6fG:vZYTybYMh[W6jbInzbZMtKEmFNUC9PU43KM7:TT6= M4WzcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N|Y{OjxxYU6=
human CCRF-CEM cells NITqWnREgXSxdH;4bYPDqGG|c3H5 MoO5O|IhcA>? NUPnSmE{S3m2b4TvfIlkcXS7IHHnZYlve3RiUHitcoVo[XSrdnWgbJVu[W5iQ1PSSk1ETU1iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJZqfGGuIHT5[UBmgGOudYPpc44w\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPU[uPEDPxE1w NEfjT5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK3N|Y{Oid-MkSyO|M3OzJ:L3G+
human SUP-B15 cells M2fHd2N6fG:2b4jpZ:Kh[XO|YYm= MmXUO|IhcA>? NGHDbGFEgXSxdH;4bYNqfHliYXfhbY5{fCCSaD3wc5NqfGm4ZTDoeY1idiCVVWCtRlE2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTD2bZRidCCmeXWg[ZhkdHW|aX;uM4Ztd3diY4n0c41mfHKrYzDhcoFtgXOrczygTWM2OD14Lkig{txONg>? NF24ZXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK3N|Y{Oid-MkSyO|M3OzJ:L3G+
human DU145 cells NV\lXY9qS3m2b4TvfIlkyqCjc4PhfS=> M1HvfVczKGh? NVjzc41IS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KH[rdHHsJIR6\SCneHPseZNqd25xZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVYvPSEQvF2u MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ5M{[zNkc,OjR{N{O2N|I9N2F-
human BV173 cells NEW5SYREgXSxdH;4bYPDqGG|c3H5 NEXN[Xo4OiCq MmfUR5l1d3SxeHnjbZR6KGGpYXnud5QhWGhvcH;zbZRqfmViaIXtZY4hSlZzN{OgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KH[rdHHsJIR6\SCneHPseZNqd25xZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVYvOyEQvF2u MkfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{N{O2N|IoRjJ2MkezOlMzRC:jPh?=
human BLIN-1 cells MlT2R5l1d3SxeHnjxsBie3OjeR?= NUXtdXl4PzJiaB?= MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBRcC2wZXfheIl3\SCqdX3hckBDVEmQLUGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KH[rdHHsJIR6\SCneHPseZNqd25xZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVUvPSEQvF2u M37lW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N|Y{OjxxYU6=
mouse bone marrow cells MWLDfZRwfG:6aXRCpIF{e2G7 MnW4O|IhcA>? M1vQO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KEKFUj3BRmwh\nW|aX;uJJBzd3SnaX6gNVkxKGW6cILld5NqdmdibX;1d4Uh[m:wZTDtZZJzd3diY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJZqfGGuIHT5[UBmgGOudYPpc44w\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPUOuN{DPxE1w M2rVZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N|Y{OjxxYU6=
Sf9 insect cells NY\XSVhCTnWwY4Tpc44h[XO|YYm= NYr5UIlXOSCq NW\VXYZJUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDTNXBNKCh4MjD0c{A2PjhrIHX4dJJme3OnZDDpckBU\jliaX7z[YN1KGOnbHzzJJV{cW6pIGOxVEBieyC|dXLzeJJifGViYX\0[ZIhOSCqch?= NXH2PYc5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NFk5OTRpPkK0PFA6QDF2PD;hQi=>
mouse MN9D cells MV\GeY5kfGmxbjDhd5NigQ>? NWDkfHdQPSEQvF2= MorFTY5lfWO2aX;uJI9nKFCSMlGgZ4F1[Wy7dHnjJJN2[nWwaYSgZYN1cX[rdImgbY4hdW:3c3WgUW46TCClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhifGVibHX2[Ywh[XRiNTD1US=> M3nEPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEWwNVY2Lz5{NUC1NFE3PTxxYU6=
rat PC12 cells Mnv4SpVv[3Srb36gZZN{[Xl? NUm4[INLPSEQvF2= NGPUe4g{OCC2bzCxNlAhdWmwcx?= NVi5Sok2UW6mdXP0bY9vKG:oIGDQNmEh[2G2YXz5eIlkKHO3YoXubZQh[WO2aY\peJkhcW5icnH0JHBEOTJiY3XscJMh[XO|ZYPz[YQh[XNicHjvd5Bp[XSnIHzleoVtKGG2IEWgeW0hdWWjc4Xy[YQhOzBidH:gNVIxKG2rboOu NVzJZlRnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVAyPjVpPkK1NFUxOTZ3PD;hQi=>
mouse MN9D cells NHTaSFVHfW6ldHnvckBie3OjeR?= MYOwMlE3KM7:TR?= MWeyOEBp NULITnFsVmW3cn;wdo91\WO2aY\lJIFkfGm4aYT5JIlvKG2xdYPlJG1PQURiY3XscJMh[XO|ZYPz[YQh[XNic4TpcZVt[XSrb36gc4YhSkSQRjDlfJBz\XO|aX;uJIF1KDBwMU[geW0h[W[2ZYKgNlQhcHK| NGnwU5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC1NFE3PSd-MkWwOVAyPjV:L3G+
mouse MN9D cells MnL6SpVv[3Srb36gZZN{[Xl? M1LOSFAvOTZizszN MkfOO|IhcA>? M37yTW5mfXKxcILveIVkfGm4ZTDhZ5Rqfmm2eTDpckBud3W|ZTDNUllFKGOnbHzzJIF{e2W|c3XkJIF{KGKub3PrbY5oKG:oIGTOSk1idHCqYTDhd5Nw[2mjdHXkJJRwgGmlaYT5JIF1KDBwMU[geW0h[W[2ZYKgO|IhcHK|IHL5JHRzgXCjbjDicJVmKHO2YXnubY5oNg>? MmroQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUCxOlUoRjJ3MEWwNVY2RC:jPh?=
CHO MmK2SpVv[3Srb36gZZN{[Xl? MljuSIl{eGyjY3Xt[Y51KG:oIGuzN3Bee3CqaX7nc5NqdmViMTDwbI9{eGijdHWg[pJwdSCqdX3hckBUOVBzIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEUE9iY3XscJMtKEmFNUC9NE45PM7:TT6= MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTZzNUWxN{c,OTV4MUW1NVM9N2F-
CHO M2HY[WZ2dmO2aX;uJIF{e2G7 NGHNWINFcXOybHHj[Y1mdnRib3[gX|M{WF2|cHjpcodwe2mwZTCxJJBpd3OyaHH0[UBnem:vIHj1cYFvKFNzUEWgdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyxiSVO1NF0zNjIQvF2u Mm\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV4MUW1NVMoRjF3NkG1OVE{RC:jPh?=
Jurkat MU\GeY5kfGmxbjDhd5NigQ>? MnK5NVghcHK| NGX0PIlT\X[ncoPhcEBw\iCrbnjpZol1cW:wIH;mJI1qfG:laH;u[JJq[WxiZoXuZ5Rqd25iaX6gbJVu[W5iSoXyb4F1KGOnbHzzJIFnfGW{IEG4JIhzeyCrbjDwdoV{\W6lZTDv[kBbNV[DRD3mcYs> M4HDNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NECwOVU2Lz5zN{SwNFU2PTxxYU6=
T-cells NYDNdmZmTnWwY4Tpc44h[XO|YYm= M4fqfVk3KGi{cx?= NIPpSFNKdW23bn;zeZBxemW|c3n2[UBi[3Srdnn0fUBqdiCEQVzCM4MwSzV5QlyvOkBud3W|ZTDUJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYXzsc4FvfGmpZX6tbY5lfWOnZDDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiOU[gbJJ{KGK7IH3lZZN2emmwZzDbN2hefGi7bXnkbY5mKHWydHHr[UBjgSCvaYjl[EBtgW2yaH;jfZRmKHKnYXP0bY9vKGG|c3H5MEBKSzVyPUCuNFA3Oc7:TT6= MnqzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NU[1NlQoRjJzNEW2OVI1RC:jPh?=
SK-BR-3 MoTYRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M3fFSVc5KGi{cx?= MknSRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVSz3CVk0{KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFc5KGi{czDifUBYW1RvMTDhd5NigSxiSVO1NF02|ryPLh?= NXu2TIV4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OVY2OjRpPkKxOFU3PTJ2PD;hQi=>
MDA-MB-231 NEX6WnNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NVvje4dEPzhiaILz NYfNWHJySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEe4JIhzeyCkeTDXV3QuOSCjc4PhfUwhUUN3ME21{txONg>? NX;MfVZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OVY2OjRpPkKxOFU3PTJ2PD;hQi=>
HCT116 NWnmPIxFSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M13ueFc5KGi{cx?= MlvyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|ghcHK|IHL5JHdUXC1zIHHzd4F6NCCLQ{WwQVXPxE1w MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR3NkWyOEc,OjF2NU[1NlQ9N2F-
SW620 Mne5RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NVnpWnNSPzhiaILz MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOZNkKwJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEe4JIhzeyCkeTDXV3QuOSCjc4PhfUwhUUN3ME21{txONg>? M4ThfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW2OVI1Lz5{MUS1OlUzPDxxYU6=
MCF7 MoLBRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NXniUpR7PzhiaILz MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{igbJJ{KGK7IGfTWE0yKGG|c3H5MEBKSzVyPUZOwG0v NXr3PWdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OVY2OjRpPkKxOFU3PTJ2PD;hQi=>
LNCAP-AI M3X2VGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MoH0O|ghcHK| M3TFPGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIh2dWGwIFzOR2FRNUGLIHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd6IHjyd{BjgSCZU2StNUBie3OjeTygTWM2OD13zszNMi=> MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR3NkWyOEc,OjF2NU[1NlQ9N2F-
MGC803 NVO1ZpNtSW62aYT1cY9zKGG|c3H5 MWexNEBu\y:tZx?= NVH1VWlyOjBiZHH5dy=> NHjz[YdCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNS2M5ODNiY3XscJMhgGWwb3fyZYZ1\WRiaX6gcpVl\SCvb4Xz[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJR2dW:{IHfyc5d1cCCjdDCxNEBu\y:tZzDmc5IhOjBiZHH5dy=> M2rWelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW2OVI1Lz5{MUS1OlUzPDxxYU6=
U2OS M{m4VGZ2dmO2aX;uJIF{e2G7 NXqyNIE1OThiaILz M2j5emFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gV|FROSC{ZXPldJRweiCneIDy[ZN{\WRiaX6gSWRIOS2kbHGgWVJQWyClZXzsd{BqdmO3YnH0[YQh\m:{IEG4JIhzeyCycnnvdkB1dyCJZX7CcIF7\XJic4Xid5Rz[XSnIHHk[Il1cW:wIHL5JIJmfGFvYYLy[ZN1cW5icnXjdpVqfG2nboSgZZN{[XluIFXDOVA:OC5yMEey{txONg>? MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ6N{S4O{c,OjZ4OEe0PFc9N2F-
FL5.12A NH7GVZpEgXSxdH;4bYNqfHliYYPzZZk> NHvFTZM1QCCqcoO= NFK3ZotEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBHVDVwMULBJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCGQWDJJJN1[WmwaX7nMYJie2WmIH\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyxiSVO1NF0zNjUQvF2u NX3q[npCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0O|U2OzRpPkK3OFc2PTN2PD;hQi=>
SH-SY5Y NFrhRmdEgXSxdH;4bYNqfHliYYPzZZk> MmDENlQhcHK| M1jMVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNJNVO\NWmgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOjRiaILzJIJ6KGO{eYP0ZYwufmmxbHX0JJN1[WmwaX7nJIJie2WmIHHzd4F6NCCHQ{GwQVAvPTUQvF2u M4n0U|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGzNVE2Lz5{N{mxN|EyPTxxYU6=
SK-N-SH MnTSR5l1d3SxeHnjbZR6KGG|c3H5 Ml\TNlQhcHK| M4j2c2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMNU5vU1igZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOjRiaILzJIJ6KGO{eYP0ZYwufmmxbHX0JJN1[WmwaX7nJIJie2WmIHHzd4F6NCCHQ{GwQVAvPTYQvF2u NVrzPFkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVMyOTVpPkK3PVE{OTF3PD;hQi=>
U118MG MYPDfZRwfG:6aXPpeJkh[XO|YYm= M4PsfFI1KGi{cx?= NFSwUphEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWOTF6TVegZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhOjRiaILzJIJ6KGO{eYP0ZYwufmmxbHX0JJN1[WmwaX7nJIJie2WmIHHzd4F6NCCHQ{GwQVAvPjIQvF2u MnnuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUOxNVUoRjJ5OUGzNVE2RC:jPh?=
SH-SY5Y MUjGeY5kfGmxbjDhd5NigQ>? M1;0OGFod26rc4SgZYN1cX[rdImgZZQhe3CqaX7nc5NqdmVvMT3wbI9{eGijdHWgdoVk\XC2b4KgbY4hcHWvYX6gV2guW1l3WTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBkSU2SIHzleoVtKGG2IFXDNVAh[nliZHny[YN1KGmvbYXuc4F{e2G7 MmG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUOxNVUoRjJ5OUGzNVE2RC:jPh?=
U118MG NInJSXdHfW6ldHnvckBie3OjeR?= MXLB[49vcXO2IHHjeIl3cXS7IHH0JJNxcGmwZ3;zbY5mNTFvcHjvd5Bp[XSnIILlZ4VxfG:{IHnuJIh2dWGwIGWxNVhOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDjRW1RKGyndnXsJIF1KEWFMUCgZpkh\Gm{ZXP0JIludXWwb3Hzd4F6 MoPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUOxNVUoRjJ5OUGzNVE2RC:jPh?=
SK-N-SH NV7IbphMTnWwY4Tpc44h[XO|YYm= NEG4W2xC\2:waYP0JIFkfGm4aYT5JIF1KHOyaHnu[49{cW6nLUGtdIhwe3CqYYTlJJJm[2WydH;yJIh2dWGwIGPLMW4uW0hiY3XscJMh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZ2FOWCCuZY\lcEBifCCHQ{GwJIJ6KGSrcnXjeEBqdW23bn;hd5NigQ>? MnfuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUOxNVUoRjJ5OUGzNVE2RC:jPh?=
HEK293 MkTLSpVv[3Srb36gZZN{[Xl? MV6xPEBpenN? NGXqRnBC\2:waYP0JIFkfGm4aYT5JIF1KHOyaHnu[49{cW6nLUGtdIhwe3CqYYTlJJJm[2WydH;yJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiClQV3QJIxmfmWuIHH0JGVEOTBiYX\0[ZIhOThiaILzJIJ6KEOURT3y[ZNxd26|aY\lJJJmdmmubHGgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6 M{\qfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGzNVE2Lz5{N{mxN|EyPTxxYU6=
SJ-GBM2 NWnLZnBJeUiWUzDhd5NigQ>? M4\QSZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz NEjZZnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
A673 MlTvdWhVWyCjc4PhfS=> M{myR5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC NWS2TmpbeUiWUzDhd5NigQ>? NYS5V206eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> M2nMOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37 MoPwdWhVWyCjc4PhfS=> MnHXdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| NXe0VphqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 MXjxTHRUKGG|c3H5 MnvFdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ|Eh[2WubIO= NWW0PIpFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 Mnj4dWhVWyCjc4PhfS=> M{Kwc5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH MVPxTHRUKGG|c3H5 MX;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= NVzoVpl6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 NGrLNFhyUFSVIHHzd4F6 M1KzXZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO= MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LAN-5 NHnVWXJyUFSVIHHzd4F6 M{\LUZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?= M1TCV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12 NX3CZpB[eUiWUzDhd5NigQ>? NF;t[o9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO= NV3uTGRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18 NYPZNYh6eUiWUzDhd5NigQ>? NELZco1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?= NUDVc4xLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 NHu4fIFyUFSVIHHzd4F6 NGLXT5ByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz NUPBVZZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD M{TtdJFJXFNiYYPzZZk> M4TjWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) M{\oTJFJXFNiYYPzZZk> M{jBSZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?= NHvvNYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh30 NUPpUlI1eUiWUzDhd5NigQ>? NGnsR|lyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?= MkC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 NHLXPW1yUFSVIHHzd4F6 Mk\YdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN? NH25O3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
FL5.12 MWPDfZRwfG:6aXPpeJkh[XO|YYm= M3vGV|Q5KGi{cx?= NVX4O|NXS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhTkx3LkGyJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCGQWDJJI9zKHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG|ZXSg[oxwfyCleYTvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTJwMd88UU4> MoLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{OUK4PVgoRjNyMkmyPFk5RC:jPh?=
FL5.12 NUjTdWoyS3m2b4TvfIlkcXS7IHHzd4F6 NW\pcpZvOTBidV2= NGK1PFU{KGi{cx?= NHfGTlBEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBHVDVwMUKgZ4VtdHNiYYPz[ZN{\WRiYYOgeoFkfW:uZTDmc5Ju[XSrb36gZZQhOTBidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJI1q[3Kxc3PvdIlkKGGwYXz5d4l{ NEPhb409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEK5Nlg6QCd-M{CyPVI5QTh:L3G+
FL5.12 M2HC[mN6fG:2b4jpZ4l1gSCjc4PhfS=> M2jmN|IvPSC3TR?= NXnWcoF5OyCqcoO= M2[3dGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGZNPS5zMjDj[YxteyCjc4Pld5Nm\CCjczD2ZYN2d2ynIH\vdo1ifGmxbjDheEAzNjVidV2gZYZ1\XJiMzDodpMh[nliZnz1c5Jme2OnbnPlJI1q[3Kxc3PvdIlkKGGwYXz5d4l{ NEjqWYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEK5Nlg6QCd-M{CyPVI5QTh:L3G+
HepG2 NUT3O2t1eUiWUzDhd5NigQ>? MmT4TIVxTzJiY3XscJMhfmmjYnnsbZR6KHGKVGOg[o9zKFqra3GgeolzfXNiaX7obYJqfG:{cx?= NI\1WnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|M{KyPVU1PSd-M{OyNlk2PDV:L3G+
CHO NIXOUJlHfW6ldHnvckBie3OjeR?= NGG2PVVC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHMyWDNicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDjZYxkcXWvIH\seZgh[nliYXXxeY9zcW5vZHXybZZm\CCudX3pcoV{[2WwY3WgZZN{[XluIFXDOVA:Oi53MUG4Pe69VS5? NV7DZmJ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzF2OEW0M{c,S2iHTVLMQE9iRg>?
CHO MoLPSpVv[3Srb36gZZN{[Xl? Mne1RYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDTNXA2KHKnY3XweI9zKGW6cILld5Nm\CCrbjDDTG8h[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iY3HsZ4l2dSCobIX4JIJ6KGGncYXvdolvNWSncnn2[YQhdHWvaX7ld4NmdmOnIHHzd4F6NCCHQ{WwQVMvOTZ{MklOwG0v MonZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|E1QDV2Lze+R4hGVUKOPD;hQi=>
Assay
Methods Test Index PMID
Western blot p-AKT / AKT / p-mTOR / mTOR / p-GSK3β / GSK3β / p-IKKα/β / IKKα / NF-κB / Survivin ; p-STAT3 / STAT3 / Bcl-xl / Bcl-2 / Bax ; Cyclin D1 / CDK4 / cyclin E / CDK2 / p27 / p16 28717222 25344679
Immunofluorescence NF-κB ; N-cadherin / Vimentin 28717222 25344679
Growth inhibition assay Cell viability 28717222
In vivo FTY720 is effective in Ph+ but not Ph- ALL xenografts using an early disease model. FTY720 produces a significant reduction in disease burden in the Ph+ ALL xenografts using an early disease model. Ph+ human ALL xenografts responds to FTY720 with an 80 % reduction in overall disease if treatment has been initiated early on. In contrast, treatment of mice with FTY720 does not result in reduced leukemia compared to controls using four separate human Ph- ALL xenografts. [3]

Protocol (from reference)

Cell Research:[1]
  • Cell lines: Immature DCs
  • Concentrations: 10 nM
  • Incubation Time: 4 hours
  • Method: Immature DCs are left intact or are incubated with 2 μM S1P, 10 nM FTY720, 10 nM SEW2871 or the combinations of S1P with these drugs for 4 hours. As a control 1 μg/mL LPS is used. The cells are washed and incubated in a 96-well plate (v-bottom, 2 × 105 cells per well), washed again and resuspended in PBS buffer containing 0.1% sodium azide. They are labeled with 1 μg/mL FITC-conjugated mouse anti-human CD80, 1 μg/mL FITC-conjugated mouse anti-human CD83, 1 μg/mL FITC-conjugated mouse anti-human CD86, 1 μg/mL FITC-conjugated mouse anti-human HLA-class I, 1 μg/mL FITC-conjugated mouse anti-human HLA-DR, 1 μg/mL FITC-conjugated mouse anti-human HLA-E, or 1 μg/mL FITC-conjugated mouse IgG as a control. The cells are washed twice, and examined in the flow cytometer. Markers are set according to the isotype control FITC-conjugated mouse IgG. To stain NK cells with antibodies for various NK cell activating receptors, they are either left untreated or incubated with 2 μM S1P for 4 hours, washed and stained with 1 μg/mL PE-conjugated mouse anti-human NKp30 (CD337), 1 μg/mL PE-conjugated mouse anti-human NKp44 (CD336), 1 μg/mL PE-conjugated mouse anti-human NKG2D (CD314), or as a control 1 μg/mL PE-conjugated mouse IgG1, for 45 min at 4 °C. NK cells are also stained with 1 μg/mL FITC-conjugated anti-killer inhibitory receptor (KIR)/CD158 antibody which recognizes KIR2DL2, KIR2DL3, KIR2DS2 and KIR2DS4, and as a control with FITC-conjugated mouse IgG. The cells are washed twice, and examined in the flow cytometer. Markers are set according to the isotype control PE-conjugated or FITC-conjugated mouse IgG.
  • (Only for Reference)
Animal Research:[3]
  • Animal Models: NOD/SCIDγc−/− mice bearing ALL cells.
  • Dosages: 5 mg/kg/day, 10 mg/kg/day
  • Administration: Administered via i.p.
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 69 mg/mL
(200.63 mM)
Water 69 mg/mL
(200.63 mM)
Ethanol ''69 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 343.9
Formula

C19H33NO2.HCl

CAS No. 162359-56-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03345940 Terminated Drug: Fingolimod|Drug: Dimethyl Fumarate Relapsing Remitting Multiple Sclerosis Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Patient-Centered Outcomes Research Institute|Universita degli Studi di Genova April 30 2017 Phase 4
NCT02575365 Terminated Drug: 05 mg Fingolimod Cognition|Brain Volume Loss Novartis Pharmaceuticals|Novartis February 16 2016 Phase 4
NCT02490930 Completed Drug: Fingolimod Glioblastoma|Anaplastic Astrocytoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins July 2015 Early Phase 1

(data from https://clinicaltrials.gov, updated on 2021-09-06)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl supplier | purchase Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl cost | Fingolimod (FTY720) HCl manufacturer | order Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl distributor